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Abstract Endothelial damage and dysfunction are implicated in cardiovascular pathological
changes and the development of vascular diseases. In view of the fact that the spontaneous
endothelial cell (EC) regeneration is a slow and insufficient process, it is of great significance
to explore alternative cell sources capable of generating functional ECs to repair damaged
endothelium. Indeed, recent achievements of cell reprogramming to convert somatic cells
to other cell types provide new powerful approaches to study endothelial regeneration. Based
on progress in the research field, the present review aims to summarize the strategies and
mechanisms of generating endothelial cells through reprogramming from somatic cells, and
to examine what this means for the potential application of cell therapy in the clinic.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
Vascular endothelial cells (ECs) array the most inner layer of
the entire circulatory system, from the largest arteries and
veins to the smallest capillaries and serve as a semi-selective
and non-adherent interface between blood and the under-
lying cells of the vessel wall such as smooth muscle cells
(SMCs), pericytes and connective tissues. ECs play a key role
in critical vascular functions, such as permeability, interac-
tion with circulating platelets and leukocytes, regulation of
vascular tone and growth. EC dysfunction or damage pre-
cedes the development of many vascular pathological con-
ditions such as peripheral vascular disease, hypertension and
atherosclerosis.1 Chronic exposure to cardiovascular risk
factors such as diabetes, hyperlipidaemia or smoking,
compromises the integrity of the endothelium and
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atherosclerosis occurs in the vessel wall. When the disease
progresses severely, a treatment with angioplasty is
routinely used in clinic. However, there is a risk of thrombosis
due to the loss-of ECs. The regeneration of endothelium in
this case is a slow process and there is currently no effective
drug or gene therapy to promote it. Recently, efforts to
achieve endothelial repair have shifted to stem cell-based
approaches. Endothelial progenitor cells (EPCs) and plurip-
otent embryonic stem cells (ESCs) can be isolated, easily
expanded and then differentiated into EC to be used for stem
cells-based cellular therapies.2e8
A third source of stem cell that has great potential for
regenerative medicine is the induced pluripotent stem (iPS)
cells. iPS cells are pluripotent cells engineered from
terminally differentiated somatic cells through a process
called reprogramming. iPS cells exhibit the cellular char-
acteristics that are highly similar to ESCs.9e11 However, iPS
cells avoid the ethical and immunological issues associated
with the application of ESCs. Moreover, iPS cells can be
generated and individualised for patient-specific therapies,
disease modelling and drug screening. iPS cells are capable
of differentiating into all cardiovascular cells including ECs,
vascular mural cells, SMCs, and cardiomyocytes and
therefore have a great potential for vascular regeneration.
Nevertheless, this strategy is time consuming and raises
tumour-forming hazards. To avoid issues associated with iPS
cells, researchers start to explore direct cell fate conver-
sion between two differentiated cell types without passing
through the pluripotent state. This strategy called direct
reprogramming opens up an exciting new area of research
for cell-based therapy.
In the present review, we aim to summarize the recent
progress in cell reprogramming technique for endothelial
regeneration, to discuss the mechanisms involved, and to
highlight the potential clinical application.
Vascular endothelial cells and endothelial
functions
Blood vessels are composed of three layers: the innermost is
the tunica intima, which is composed of a single continuous
layer of endothelial cells and mediates the exchange of nu-
trients and cells with the circulation. Surrounding the intima
is the thick layer of smoothmuscle cells composing the tunica
media, which is responsible for themaintenance of the vessel
tone and elasticity. Finally, adventitia is the external layer
mainly composed of fibroblasts and connective tissue and
incorporating the vasa vasorum, the small network of vessels
that provides oxygen and nutrients to the cells in the vessel
wall. Vessels within themicrovascular system (i.e. capillaries
and venules) are formed by contractile cells called pericytes
that wrap around the EC layer.12 ECs are key components for
maintaining the function of the vessels. ECs are actively
involved in regulating endothelium permeability, modulating
vascular tone, regulating blood coagulation, and many other
biological processes.
The integrity of the endothelium is the foundation of
vascular homeostasis. The cellecell junctional structures,
which link EC with each other to form a continuous mono-
layer, profoundly contribute to the regulation of perme-
ability and the maintenance of the endothelium integrity.
Furthermore, EC junctions actively participate in trans-
ferring intercellular signals between adjacent cells. EC
junctions are formed by transmembrane adhesive proteins
linked to specific cytoplasmic and cytoskeletal molecules.13
Endothelium regulates vascular tone through secreting
EC-derived vasodilators including NO, prostacyclin and
other factors. These EC-derived factors mediate the
relaxation of SMCs to achieve vasodilation. NO is recognised
as the primary factor for vasodilation which is synthesised
in ECs by eNOS and that is dependent on its cofactors
including free calcium (Ca2þ) and L-arginine.14 In addition
to the modulation of vascular tone, NO also has other
vessel-protective roles including regulating the growth of
local cells, inhibiting the aggregation and adhesion of in-
flammatory cells and platelets to endothelial surface.15
Healthy ECs possess anticoagulant and antithrombotic
functions to keep the vascular patency. Blood coagulation is
prevented by ECs through synthesising and displaying in-
hibitors for tissue factor pathway and thrombin. ECs also
express molecules for protein C activation which can
demolish certain clotting factors and inhibits coagulation.16
ECs can physically separate the interaction of platelets
with collagen which can activate platelets. ECs also secrete
antiplatelet molecules like prostacyclin, NO and prosta-
glandin-E2 to inhibit the adhesion and activation of plate-
lets on the endothelial surface.17 Under physiological
condition, endothelium prevents the inflammatory cells
adhesion by failing to express adhesion molecules that
mediate leukocytes attachment.
Endothelial dysfunction in vascular diseases
The dysfunction of the endothelial monolayer is the key
initiation event of vascular diseases caused by a variety of
stimuli including hypertension, diabetes, dyslipidaemia,
oxidative stress and others. Endothelial dysfunction is
characterised by leukocytes recruitment and platelet ag-
gregation, increased permeability, thrombus formation,
and impaired endothelium-mediated vasodilation. The
expression of surface adhesion molecules are changed
within the injured ECs which initiate the recruitment of
blood leukocytes and platelets. In parallel, the endothe-
lium permeability and the sub-endothelial extracellular
matrix composition are altered to permit the penetration
and accumulation of leukocytes and oxidised LDL parti-
cles.18 The NO synthesis capacity of ECs is also disturbed
during atherosclerosis which impairs the endothelium-
dependent vasodilation. Reduced NO synthesis occurs
simultaneously with the increased generation of reactive
oxygen species (ROS). Increased ROS bioavailability,
together with the dysregulated oxidative stress, further
damages the endothelial homeostasis.19 To repair the
injured endothelium and reconstruct normal endothelial
physiological function is a major target for therapy against
vascular disease.
After endothelial dysfunction and denudation during
vascular disease or treatment with angioplasty, endogenous
resident ECs tend to proliferate and replace the injured
endothelium. A number of studies from early years showed
that local ECs participate in the repair of small areas of
endothelial damage through migration and the repair of
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larger areas of damage through both proliferation and
migration.20 Recently, by transplanting wire-injured carotid
artery segments from wild type mice into Tie2-GFP mice,
Hagensen et al demonstrated the resident ECs from the
transplanted graft contribute to the re-endothelialisation
of the lesion.21
Although the proliferation and migration of resident ECs
represent a straightforward way for endothelial regenera-
tion, it is a relatively slow and inefficient process.22 In
addition, with the effects of the cardiovascular risk factors,
the adjacent ECs around injured endothelial area may also
be in a dysfunctional state. The rejuvenation of ECs with
normal function represents a significant target of vascular
disease therapies. A number of different stem cell sources,
that have been considered to contribute to EC regenera-
tion, potentially provide promising methods for regenera-
tive medicine. In this review, we will focus on the
generation of ECs through reprogramming technique.
Induced pluripotent stem cell and endothelial
regeneration
In 2006, Takahashi and Yamanaka first described the process
of converting a lineage-committed somatic cell back to the
pluripotent state by simultaneously overexpressing four
transcription factors Oct4, Sox2, Klf4 and c-Myc using viral
vectors.10 This Nobel Prize-winning hallmark study success-
fully reprogrammed mouse fibroblasts to a new type of
pluripotent cell that highly resembled ESC in morphology,
proliferation, gene expression and DNA methylation pat-
terns. The newly generated cell population was termed
“induced pluripotent stem cell” or iPS cell. Since then, iPS
cells have been successfully generated from different so-
matic cell types with different combinations of reprogram-
ming factors and various induction methods, which proved
the universality of the concept of cell reprogramming.23
iPS cells have the potential to differentiate towards
vascular cell lineages including ECs. ECs can be derived
from iPS cells by using three approaches: embryoid body
(EB) formation, coculture with feeder cells or defined
chemical condition. In 2009, two groups first showed that
ECs could be generated from human iPS cells. Choi et al
cocultured different human iPS cell lines with OP9 feeder
cells for 8 days and then selected CD34- and PECAM-1-
double positive cell population which could give rise to
functional ECs after 7 days under endothelial-promoting
culture conditions.24 Using a similar approach, Taura et al
cocultured human iPS cells with OP9 feeder cells for 10 days
and observed the emergence of a VEGFR2-positive popu-
lation with EC differentiation capacity.25 Endothelial
lineage-committed cells could also be derived from EB
formed by iPS cells.26 Most commonly, feeder-free culture
systems with the combination of different culture sub-
strates and chemical conditions have been successfully
applied to induce ECs from iPS cells.27
iPS-ECs display similar features with mature ECs at the
genetic and functional levels. A major advantage of using
iPS cells as EC source is the abundant origins of iPS cells and
the potential to generate patient individualised ECs that
bypass the immunogenicity and ethical issues. iPS-ECs have
been tested in peripheral vascular disease mouse model to
show their neoangiogenic capacity that led to the
improvement of blood perfusion of ischaemic tissue.26
In spite of the fact that iPS cells start a new era of
regeneration medicine, the tumourigenesis risk jeopardises
their further clinical applications. The fact that many
reprogramming factor cocktails contain oncogenes and
many gene delivery methods use viral vectors raise the risk
of tumour formation in vivo.28 In addition, iPS cells exhibit
more genetic and epigenetic instability compared to ESC
due to the artificial reprogramming process.29 Therefore,
there is still a long way to go before the mature utilisation
of iPS cells at the bedside. Cell direct reprogramming
techniques to convert cell fate between two differentiated
cell types without passing through the pluripotent state
provide new possibilities for endothelial rejuvenation.
Direct cell lineage reprogramming and endothelial
regeneration
Presently, basedon theuseof transcription factors, there are
two dominant reprogramming strategies to achieve direct
cell lineage conversion. One is through introducing various
combinations of target cell type-specific transcription fac-
tors to directly drive cell lineage switch. In 2008, a case of
in vivo study demonstrated the direct conversion of
pancreatic exocrine cell to functional b-cell by injecting
adenoviruses encoding three transcription factors Nng3,
Pdx1, and Mafa into adult mice pancreas.30 In 2010, via the
overexpression of Gata4, Mef2c, and Tbx5, Srivastava’s
group directly reprogrammed cardiac fibroblasts into func-
tional cardiomyocytes in vitro.31 The same group subse-
quently showed the in vivo reprogramming ofmurine cardiac
fibroblasts into cardiomyocytes through intra-myocardial
injection of the identical set of the three transcription fac-
tors.32 In addition, a variety of reports provided evidence of
directly reprogramming fibroblasts into other cell types
including neurons, hepatocytes, etc.33,34
Another fast and efficient approach to modulate cell
fate is based on the use of iPS-generating pluripotency
factors such as Oct4, Sox2, Klf4, Nanog, etc to erase lineage
particular signatures and reactivate repressed epigenetic
network as a first step, but with shorter reprogramming
time and different culture conditions to avoid the full in-
duction of pluripotency. After this step, cells revert to an
intermediate plastic state which permits further manipu-
lations towards the desired cell types. Short term reac-
tivation of reprogramming genes Oct4, Sox2, and Klf4 plus
chemically defined media and cardio-inductive growth
factor BMP4 converted embryonic and adult fibroblasts to
functional cardiomyocytes.35 During the conversion, the
role of reprogramming factors is to erase the original cell
identity via epigenetic mechanisms, instead of directly
activate cardiomyocyte-specific genes.
Direct endothelial reprogramming with EC-related
transcription factors
Ectopic overexpression of endothelial related transcription
factors has been applied to generate ECs from other so-
matic cell types. Ginsberg et al first reported the direct
reprogramming of human amniotic fluid-derived cells into
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ECs by ETS transcription factors ETV2, FLI1, and ERG1
together with TGF-b suppression.36 ETS transcription fac-
tors are potent regulators for vascular development and
angiogenesis and they regulate almost all typical endothe-
lial markers.37 EC-specific genes can be switched on within
4 days of ectopic expression of ETV2, FLI1, and ERG1 with
TFG-b suppression. However, to establish stably prolifera-
tive EC population, a more precise temporal control on
gene overexpression is needed. Recently, there were two
important studies published, relative to the direct conver-
sion of fibroblasts into ECs through the overexpression of
selected endothelial related transcription factors. Han et al
converted mouse adult fibroblasts into ECs using a cocktail
of five transcription factors: Foxo1, Etv2, Klf2, Tal1 and
Lmo2.38 All of these five factors play crucial roles in
vascular development and endothelial maturation. Inter-
estingly, authors from this study tried to use Etv2, Erg and
Fli1 to reprogram mouse adult fibroblasts as shown in
Ginsberg’s study. However, they did not observe any EC
generation. On the contrary, including Erg or Fli1 into their
reprogramming factor cocktail compromised EC reprog-
ramming efficiency from fibroblasts. This finding indicates
that for different cell types, specific optimisation of tran-
scription factors combination and culture condition is
required for successful endothelial reprogramming.
Another study showed that solely overexpressing one ETS
transcription factor ETV2 is sufficient to induce functional
ECs from human adult fibroblasts.39 The ETV2 expression
level needs to be carefully controlled. Too low or too high
ETV2 expressions both jeopardise the endothelial reprog-
ramming efficiency from fibroblasts. In addition to ETV2
overexpression, the endogenous FOXC2 expression in the
human adult fibroblasts is essential for ETV2 to induce EC
reprogramming.
Although using the target cell-specific transcription fac-
tors for direct cell lineage reprogramming represents a
straightforward strategy, a major concern related to this
method is that the original gene regulatory network of the
starting cell typemay be insufficiently inactivated. Indeed, a
recent study provided evidence to support this concern by
comparing the gene expression patterns of various directly
reprogrammed cell types with cells derived from pluripotent
stem cells using a computational network biology platform
named CellNet. Comprehensive analysis showed that
directly reprogrammed cells tend to inadequately silence
the expression programs of the starting cell population.40
This suggests that using target cell-specific transcriptions
factors to conduct the direct cell lineage conversion may fail
to fully erase the identity of the starting cell type and result
in the incomplete establishment of the gene regulatory
networks of the target cell type.
Direct endothelial reprogramming using iPS-
generating factors
Short term overexpression of iPS-generating pluripotency
factors has been used to induce the plasticity of somatic
cells which leads to further differentiation towards endo-
thelial lineage. By overexpressing Oct4, Sox2, Klf4 and
c-Myc for 8 days, fibroblasts were reverted to an interme-
diate CD34-positive mesodermal progenitor state which
could be further differentiated towards endothelial or
smooth muscle lineages under different stimulating condi-
tions.41 The authors discussed that all four factors are
requisite for the generation of CD34-positive cells. To
remove any single factor leads to the failure of the meso-
dermal progenitor state induction. Converted EC is a mixed
population of different endothelial subtypes including
arterial, venous and lymphatic ECs. Studies from our lab
showed that reprogramming human fibroblasts with OCT4,
SOX2, KLF4, and c-MYC for 4 days generated partial-iPS
(PiPS) cells with an upregulation of VEGFR2. PiPS cells
have the ability to differentiate into both endothelial- and
smooth muscle-like cells.42,43 Functional ECs could be
derived from PiPS cells after 6 days of differentiation in
endothelial-inductive condition. Another study reduced
the transcription factors to Oct4 and Klf4 to obtain func-
tional endothelial cells transdifferentiated from human
fibroblasts.44
To use reprogramming factors, especially the oncogene
c-MYC, as part of the protocol still raises tumourigenesis
concerns. Although teratoma formation has not been
observed in the in vivo experiments of any studies, the long
term effect of using reprogramming factors is difficult to
predict. Two recent papers discussed the direct reprog-
ramming strategy using pluripotent factors induced tran-
sient pluripotent state at certain stage of the protocol.45,46
Further studies need to clarify the exact roles of pluripo-
tent factors in direct reprogramming and the transitions of
cell identity during the transdifferentiation.
Direct endothelial reprogramming using small
molecules
Beyond the use of transcription factors, recent studies
exploited novel approaches including microRNAs (miRNAs),
epigenetic regulators, signal pathwaysmodulators and other
small molecules to drive cell lineage conversion. Condition-
ally adding these small molecules into the transcription
factors cocktail can boost the efficiency of cell fate switch-
ing. Furthermore, some combinations of the small molecules
alone could drive direct lineage conversion without the
ectopic overexpression of transcription factors.47 A recent
study demonstrated the transdifferentiation of human fi-
broblasts to endothelial cells using small molecule activators
of toll-like receptor 3 (TLR3) combined with endothelial
growth factors.48 TLR3 agonist Poly I:C activates innate im-
mune signalling which leads to increased epigenetic plas-
ticity for cell fatemanipulation. Histonemodifications at the
promoter regions of PECAM-1 have been observed during the
fibroblast to EC conversion.
Comparison of different stem cell-based
strategies for EC generation
In the above sessions,wehave discussed EC generation based
on different reprogramming techniques (Fig. 1). Because of
the critical role that ECs play in cardiovascular physiological
and pathological conditions, it is of great importance to
investigate and compare different cells sources and strate-
gies that can regenerate functional ECs and further obtain
therapeutic value. For now, three major stem cell types are
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regarded to be promising therapeutic options for endothelial
regeneration: EPC, ESC, and iPS cell. In addition, the emer-
gence of direct cell reprogramming provides novel powerful
cell sources. The advantages and deficiencies of these cell
types and their clinical application value are briefly sum-
marised as follow (Table 1).
Mechanisms involved in endothelial
reprogramming
From the ectopic overexpression of different sets of tran-
scription factors, to the following modulation of signalling
pathways and endothelial-inductive conditions, mecha-
nisms from many aspects have been implicated in the
endothelial reprogramming process (Fig. 2). Signalling
pathways regulating endothelial differentiation have been
extensively reviewed before.27,49e51 In this review, we
focus on the mechanisms that are more related to the
generation of ECs through reprogramming.
Epigenetic modulations during endothelial
reprogramming
The conversion of cell type requires the fundamental
resetting of the epigenome. The epigenetic signature of the
starting cell type needs to be erased and a new epigenetic
signature of the converted cell type needs to be estab-
lished. The epigenetic modulations include chromatin
reorganisation, DNA methylation changes, post-
translational histone modification, etc. Many studies have
shown the epigenetic changes along endothelial reprog-
ramming. Furthermore, EC reprogramming can be achieved
by targeting the epigenetic level instead of the
transcriptional level. Using a small molecule of TLR3
agonist to active innate immunity could increase epigenetic
plasticity and lead to the direct reprogramming of fibro-
blasts to ECs.48 However, the detailed mechanisms and
regulatory factors involved in the process are not clear yet.
DNA methylation profile is an important epigenetic
signature of a committed cell type. Switching from one cell
type to another requires the universal DNA demethylation
towards the establishment of a new cell identity.52 ECs
converted from fibroblasts through CD34-positive meso-
dermal progenitor state using OCT4, SOX2, KLF4, and c-MYC
lost the DNA methylation profile of fibroblasts 33. The
promoter regions of VE-Cadherin and Tie2 were demethy-
lated in the induced ECs derived from fibroblasts by Foxo1,
Etv2, Klf2, Tal1 and Lmo2.38
Histone modifications play fundamental roles in con-
trolling the expression of the genes. Histone repressive
marker H3K27me3 at PECAM-1 and VE-Cadherin promoter
regions were significantly decreased during the conversion
of fibroblasts towards ECs using Oct4 and Klf4.44 The his-
tone active marker H3K4me3 was increased in the promoter
regions of PECAM-1 together with the decrease of the
H3K27me3 mark at the same regions during the reprog-
ramming of fibroblasts towards ECs with TLR3 agonist.48
Cell plasticity induced by pluripotency
reprogramming factors
Since the establishment of reprogramming technique to
generate pluripotent iPS cells from lineage-committed so-
matic cells, researchers have endeavoured to exploit the
underlying molecular mechanisms. In general, the complex
transcriptional and epigenetic changes of the whole
genome occur during the reprogramming to reverse the
Fig. 1 Reprogramming strategies for endothelial generation from other types of somatic cells. Somatic cells can be reprog-
rammed towards the endothelial lineage with or without passing through a pluripotent state. (A) Ectopic overexpression of
endothelial-specific transcription factors with endothelial-inductive conditions can directly reprogram somatic cells into ECs. (B)
Using iPS-generating pluripotency transcription factors for a short term can switch the differentiated somatic cells to a inter-
mediate plastic state. Then the partially reprogrammed cells can be further differentiated towards ECs. (C) Somatic cells can also
be fully reprogrammed into iPS cells and then be stimulated into the endothelial fate.
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Table 1 Comparison of different stem cell-based strategies for endothelial regeneration.
Cell source Adult stem cells ESCs iPS cells Somatic cells
Origin Circulation, bone marrow
or resident tissue
Blastocyst of embryo Generated by reprogramming
of somatic cells, usually fibroblast
Many types of somatic cells:
fibroblast, amniotic cell, etc
EC generation Give rise to EC in response
to specific stimulations and
endothelial-promoting
culture conditions
EB formation and subpopulation
selection; culture with feeder
cells or specific substrate under
chemical defined endothelial-
promoting condition
Culture under chemical defined
endothelial-promoting conditions;
EB formation and subpopulation
selection
Reprogrammed by specific
transcription factor with
endothelial-promoting
culture conditions
Main strengths  Autologous
 Specific endothelial
lineage committed
 Clinical safety
 Self-renewal
 High proliferative capacity
 Autologous
 Self-renewal
 Large number of
cell sources
 Autologous
 Large number of
cell sources
 Simplicity and less
time consuming
Main weaknesses  Ambiguous definition
and isolation methods
 Limited number
 Limited replicative
capacity
 Ethical debate
 Tumourigenesis risk
 Immunological barriers
 Unstable cell identity
 Tumourigenesis risk
 Time consuming
 Unstable cell identity
 Low efficiency
 Various initial cell types
 Unstable cell identity
 Potential tumourigenesis
risk
Clinical application A number of clinical trials
proved the therapeutic
benefits for revascularisation
and remodelling
No clinical trial data. No clinical trial data No clinical trial data
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differentiated cells back to the pluripotent state. Genome-
wide analyses of the cell populations at different time
points during the reprogramming process revealed three
phases for successful iPS cell generation: initiation, matu-
ration, and stabilisation.53
Each phase is characterised by the expression of a
distinct group of genes. The initial phase is marked by a
mesenchymal-to-epithelial transition. Interestingly, the
signature genes associated with the maturation and stabi-
lisation phases are not pluripotency regulators, but rather
the genes related to cell cycle, cytoskeletal dynamics and
signalling pathways.54 Another study also used genome-
wide analyses to show that there were two major gene
expression changing waves. One occurred between 0 and 3
days, and the second wave happened between day 9 till the
end.55 Genes responsible for proliferation and metabolic
changes were activated and the genes related to fibroblast
identity were suppressed during the first wave. The second
wave was characterised by the expression of genes related
to stem cell identity establishment and epigenetic remod-
elling. These cell population-based studies suggested that
reprogramming is a multi-step process with transcriptome
resetting. The existence of multiple phases along iPS cell
generation, especially erasing the cell identity as a first
step, provides more possibilities to adjust the iPS reprog-
ramming strategy to apply on direct reprogramming by
using iPS-generating factors.
In order to understand the molecular mechanisms
regulating EC reprogramming from other cell types using
iPS-generating factors, it is important to understand the
roles of the key reprogramming factors Oct4, Sox2, Klf4,
and c-Myc at early stage of iPS cell generation. The clear
function of these four transcription factors during cell
reprogramming has not been clarified. In general, these
four factors act as pioneer factors for remodelling the
epigenome. They open up chromatin regions and bind to
the promoters of a wide range of genes to guide further
epigenetic modification.56 Interestingly, in addition to the
genes that they usually regulate in ESCs, they also bind to
the genes that are not occupied by these factors in ESCs.57
This promiscuous binding phenomenon indicated that the
roles of the reprogramming factors may be cell type
dependent. Oct4, Sox2, and Klf4 collectively form a tran-
scriptional network that associates with repressing somatic
gene expression and upregulating pluripotent genes during
reprogramming. c-Myc mainly acts as an transcriptional
amplifier at all active promoters to enhance the kinetics
and efficiency of reprogramming.58 The fact that Oct4,
Sox2, Klf4, and c-Myc are able to open chromatin and
induce cell plasticity early in reprogramming support the
direct lineage conversion strategy of transiently expressing
these four factors to dedifferentiate the somatic cell back
to an intermediate state followed by further differentiating
the cells towards another lineage.
KLF4 is particularly interesting when specifically
considering the reprogramming towards vascular cell line-
age. KLF4 has been shown to play a crucial role in regu-
lating vascular cell development and function in addition to
its reprogramming role and has been identified as an
important transcription factor for both SMC and EC. KLF4
Fig. 2 Mechanisms involved in endothelial reprogramming. Different signalling pathways together with epigenetic and tran-
scriptional regulations comprehensively modulate the reprogramming towards the endothelial lineage. Relevant signalling path-
ways include VEGF, BMP, NOTCH, TGF-b, FGF signalling pathways. Epigenetic modulations include chromatin reorganisation, DNA
demethylation, and post-translational histone modification. Transcriptional level is the wide-scale gene expression regulations
induced by ectopically overexpressed transcription factors.
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has been shown to directly bind to the promoter of VE-
Cadherin in mature ECs to improve cell barrier function.59
Another study indicated that KLF4 plays a protective role
in regulating the response of EC to inflammatory stimuli.
Overexpressing KLF4 in ECs increases the expression of
antiinflammatory and antithrombotic factors including
eNOS and thrombomodulin.60 In c-Kit-positive vascular
progenitor population derived from ESCs, Klf4 was shown to
positively regulate their differentiation towards ECs.
Overexpression of Klf4 in this population led to further
upregulation of EC markers and knockdown of Klf4 resulted
in an increase of SMC markers.61 The above studies suggest
that KLF4 may play an additional favourable role in pro-
moting reprogramming towards the endothelial lineage.
Mesenchymal-to-epithelial transition and cell
reprogramming
Among the studies related to the different phase of cell
reprogramming, a biological process named Mesenchymal-
to-Epithelial Transition (MET) has emerged to be a key
event for the initial stage of somatic cell reprogramming.
Based on the temporal changes of global gene expression,
an important study in 2010 divided the reprogramming of
mouse embryonic fibroblast (MEF) to iPS cell into three main
phases: initiation, maturation and stabilisation. Among
which, the initiation stage was characterised by the MET
driven by bone morphogenetic proteins (BMPs) signalling.53
At the same time, another group demonstrated the requi-
site role of MET at early stage for successful mouse iPS cells
generation. MET was regulated by the interactions with
reprogramming transcription factors and TGF-b signalling.62
During the generation of human iPS cells from fibro-
blasts, the participation of MET was confirmed by a study
that suggested that the reprogramming promoting function
of miRNA-302 and miRNA-372 was partly acting through
MET.63 Later on, a comprehensive proteomics analysis of
the whole course of reprogramming confirmed the exis-
tence of MET during early phase at protein level.64 Till now,
many studies have proved the occurrence of MET at early
stage for successful somatic reprogramming in different
cell systems.
In addition, recent studies indicated the involvement of
MET during the early stage of direct cell lineage conver-
sions, which suggested a more universal role of MET process
in modulating cell identity plasticity. Ectopic introduction
of transcription factors Nr5a1, Wt1 and Dmrt1 into fibro-
blasts could initiate MET as a first step and finally convert
the cells towards embryonic sertoli-like cells.65 Another
recent report on direct reprogramming of fibroblasts into
induced cardiomyocytes demonstrated the involvement of
MET.66 Promoting MET through the suppression of Snai1 by
miR-133 could profoundly enhance the protocol efficiency
and cell quality of converted cardiomyocytes.
Notch signalling mediating endothelial
differentiation
The Notch signalling pathway participates in the regulation
of diverse vascular cell function during embryonic and
postnatal development.67 The Notch signals usually function
to drive the differentiation of the precursors between two
alternative fates.68 For example, Notch signals determine
the arterial-venous fate of ECs and the tip or stalk cells
selection of ECs during angiogenesis.
JAG1 is a Serrate/Jagged family transmembrane ligand
for the Notch pathway containing multiple epidermal
growth factor-like repeats.69 JAG1, as the upstream ligand
of the transmembrane receptors in the Notch pathway,
plays a complicated role in orchestrating cell fate. The
homozygous mutation of the Jag1 gene in mice causes early
embryonic lethality due to extensive embryonic and yolk
sac vascular defects.70 The mutation of the JAG1 gene in
humans leads to Alagille syndrome characterised by
abnormal development of multiple systems during child-
hood.71,72 Vascular anomalies including pulmonary artery
abnormalities, intracranial haemorrhages and other events,
frequently occur in Alagille syndrome patients and account
for a large portion of mortality, which reflects the impor-
tant role of JAG1 during human vascular development.73
The pro-angiogenic role of Jag1 has been shown using
EC-specific and inducible knockout or overexpression in
mice. Jag1 loss-of-function mutants exhibited reduced
sprouting angiogenesis while Jag1 overexpression promotes
sprouting angiogenesis.74 Kwon et al showed that Jag1-
induced signals from the bone marrow microenvironment
are critical for the development of angiogenic ability of
endothelial progenitor cells.75 An interesting study recently
demonstrated that JAG1 could subsequently activate KLF4
which induced the transdifferentiation of tumour cells into
endothelial cells.76 Nevertheless, there are reports of the
opposite effect in other cell models. A recent study
emphasised the role of JAG1 in promoting haematopoietic
lineage over endothelial lineage specification during
pluripotent stem cell differentiation.77 It is conceivable
that in different cell types and in response to different
environmental cues, the JAG1 activated Notch pathway
may delicately control a distinct regulation network which
leads to altered consequences.
HES5 is a common downstream target of the Notch
pathway which belongs to the basic helix-loop-helix tran-
scription factor family and is usually associated with neural
cell differentiation.78 One study suggested a role for HES5
in vascular development, as it might be a key positive
mediator for the statin-induced differentiation of bone
marrow stromal cells into ECs.79 Another study has sug-
gested that HES5 plays a part in promoting endothelial
proliferation in response to endothelial injury during
atherosclerosis.80 This study also demonstrated that
MicroRNA-126-5p promotes endothelial regeneration and
limits atherosclerosis by suppressing the Notch inhibitor
delta-like 1 homologue (Dlk1), which leads to the release of
HES5 that was suppressed by Dlk1, allowing HES5 to play its
role in endothelial repair.
Potential applications of EC generated through
reprogramming
One big advantage of using iPS cell or direct cell conversion
technique to generate ECs is the use for patient-specific
disease modelling and drug screening. Moreover, an
exceptional advantage of direct lineage conversion over iPS
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cell is the potential application for direct in vivo lineage
reprogramming for cell replacement therapy, which avoids
the unstable long term of in vitro cell culture, tumour-
forming risks and the technical obstacles for cell trans-
plantation. For example, direct injection of transcription
factors cocktail Gata4, Mef2c and Tbx5 into the infracted
cardiac area could reprogram resident non-myocytes into
cardiomyocyte-like cells with improved cardiac function.32
The in vivo regeneration of functional insulin-producing
pancreatic b-cells from other types of pancreatic cells has
been reported by several studies for their potential benefits
for treating diabetes.30,81,82
Cell-based therapeutic angiogenesis is a recently arising
approach to restore the blood perfusion in ischaemic tissue.
Successful therapeutic angiogenesis depends on the trans-
planted cells to directly incorporate into the neo-
vasculature as well as to secrete angiogenic growth
factors.83 This therapy is of special significance in treating
peripheral artery disease (PAD) since current pharmaco-
logical and interventional revascularisation therapies are
not beneficial enough.84 However, researchers are still
investigating the optimal starting cells to generate func-
tional angiogenic cells. In the murine ischaemia model of
PAD, several studies demonstrated that direct reprog-
rammed ECs could efficiently engraft into local vasculo-
genesis of ischaemic tissue and profoundly improve the
tissue perfusion.38,39,42,44,48 Moreover, direct reprogram-
ming without reversing to a pluripotent state prevents the
risk of tumour formation.
Reprogrammed ECs have the potential to become tissue-
specific ECs which provide interesting therapeutic value to
target precise pathological conditions. This could be ach-
ieved through culturing the cells under in vitro or in vivo
tissue-specificmicroenvironment. In vitro co-differentiating
ECs and neural cells from human iPS cells facilitates the
reprogrammed ECs to acquire bloodebrain barrier EC spec-
ification.85 Neural cells provide relevant cues includingWnt/
b-catenin signalling to specify the ECs towards a bloodebrain
barrier phenotype. Ginsberg et al demonstrated that amni-
otic cells-derived ECs can be specifically educated into si-
nusoidal ECs to participate liver vasculature regeneration by
intrasplenic transplantation.29 Recent studies further clarify
the molecular signatures to define tissue-specific ECs, which
provide us more information to achieve EC specification
through introducing transcription factor that regulates tis-
sue-specific EC identity.86
Tissue engineered vascular graft represents another
promising direction for vascular regenerative medicine. In
addition to direct transplantation to replace injured ves-
sels, tissue engineered graft can also serve as a useful
ex vivo model to study the mechanisms related to vascular
cell or ECM behaviours. Based on a previous established
protocol from our laboratory, functional vascular-
resembling conduits can be generated by seeding the
decellularised mouse aorta with human origin cells using an
ex vivo bioreactor circulation system.43,87 Human
fibroblast-derived ECs exhibited good ability to reendo-
thelialise the decellularised graft.42
The proliferation and accumulation of SMC and fibro-
blasts following endothelial denudation/dysfunction pro-
foundly contributes to the development of atherosclerosis
and restenosis. Protocols for the direct conversion of fi-
broblasts into functional ECs may provide promising tools
for in situ endothelial regeneration. However, the main
obstacle to this future application is the lack of proper gene
delivery technique aiming at the specific type of cell for
in vivo reprogramming. A recent study demonstrated an in
situ virus delivery method to specifically target vascular
SMCs without effecting ECs by constructing a designated
gene with EC enriched microRNA target sequences within
Fig. 3 An efficient workflow for endothelial reprogramming and applications. Based on the fast development in the field of
computational biology, an efficient workflow for endothelial reprogramming can start with using computational platform to
calculate the possible sets of transcription factors to achieve efficient reprogramming. Then the protocol can be verified and
optimised at the bench. Finally, ECs generated through reprogramming from patients can be used for individualised cell therapy
and tissue engineering, disease modelling and drug screening.
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the same vector.88 By employing a similar strategy, it is
possible to develop a method to specifically switch local
fibroblasts or SMCs into the endothelial lineage to achieve
autologous endothelium repair.
Summary and perspective
Generating functional ECs from other somatic cell types with
or without passing through a pluripotent state provides
intriguing prospects for therapeutic application of vascular
regeneration, especially to generate patient individualised
cells that bypass the immunogenicity and ethical issues.
However, the existing reprogramming methods to produce
ECs are of various efficiencies. Therefore, further optimisa-
tion and standardisation of the methods are required to be
able to produce ECs at clinical grade and scale. In addition,
the underlying mechanisms of endothelial reprogramming
need to be elucidated to facilitate the optimisation of the
technique.
The fast development in the field of computational
biology provides new tools to analyse transcription factor
combinations for efficient direct reprogramming.89e91 A
recently developed computational platform, Mogrify, pre-
dicted the sets of reprogramming factors to successfully
convert keratinocytes into microvascular ECs based on the
combined calculation of gene expression data and regula-
tory network information.90 Novel bioinformatics ap-
proaches largely facilitate the development of cell lineage
conversion protocols.
In the future, an efficient workflow could be to firstly use
computational platform to predict the possible reprogram-
ming strategy. Then to validate and optimise the reprogram-
ming protocol at the bench to efficiently generate well
characterised endothelial population. Finally the individu-
alised endothelial population couldbe applied in downstream
applications including vascular regenerative therapies,
vascular disease modelling and drug screening (Fig. 3).
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